Brain cancer vaccine shows promise in early trial

NCT ID NCT02455557

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 21 times

Summary

This study tests a vaccine called SurVaxM, given with standard chemotherapy, for people with a newly diagnosed aggressive brain cancer (glioblastoma). The vaccine is designed to train the immune system to attack cancer cells. The main goal is to see if adding the vaccine helps keep the cancer from growing for at least 6 months. About 66 participants are enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

    Cleveland, Ohio, 44195, United States

  • Dana-Farber Harvard Cancer Center

    Boston, Massachusetts, 02115, United States

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02114, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

Conditions

Explore the condition pages connected to this study.